Office Management of Melanoma Patients

Seminars in Cutaneous Medicine and Surgery

Volumn 29, Issue 4, 2010, Pages 232-237

  Brown, Marc D ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; EPILUMINESCENCE MICROSCOPY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LYMPHADENECTOMY; MALIGNANT LENTIGO; MELANOMA; PHYSICAL EXAMINATION; PROGNOSIS; REVIEW; SENTINEL LYMPH NODE BIOPSY; TUMOR BIOPSY;

COUNSELING; HUMANS; MELANOMA; NEOPLASM STAGING; PATIENT CARE MANAGEMENT; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 79251514969     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sder.2010.10.001     Document Type: Review

References (32)

1. Tucker M.A., Halpern A., Holly E.A., et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997, 277:1439-1444.
2. Bevona C., Boggins W., Quinn T., et al. Cutaneous melanomas associated with nevi. Arch Dermatol 2003, 139:1620-1624.
3. Niendorf K.B., Tsao H. Cutaneous melanoma: family screening and genetic testing. Dermatol Ther 2006, 19:1-8.
4. Johnson T.M., Hamilton T., Lowe L. Multiple primary melanomas. J Am Acad Dermatol 1998, 39:422-427.
5. Elwood J.M., Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997, 73:198-203.
6. Langley R.G., Sober A.J. A clinical review of the evidence for the role of ultraviolet radiation in the etiology of cutaneous melanoma. Cancer Invest 1997, 15:561-567.
7. Eide M.J., Weinstock M.A. Association of UV Index, Latitude, and Melanoma Incidence in Nonwhite Populations-US Surveillance, Epidemiology, and End Results SEER Program, 1992 to 2001. Arch Dermatol 2005, 141:477-481.
8. Ibrahim S.F., Brown M.D. Tanning and cutaneous malignancy. Dermatol Surg 2008, 34:460-474.
9. Gillgren P., Brattström D., Djureen Mårtensson E., et al. A new computerized methodology to analyse tumour site in relation to phenotypic traits and epidemiological characteristics of cutaneous malignant melanoma. Br J Dermatol 2002, 146:1023-1030.
10. Builliard J.L. Site-specific risk of cutaneous malignant melanoma and pattern of sun exposure in New Zealand. Int J Cancer 2000, 85:627-632.
11. Nagore E., Oliver V., Moreno-Picot S., et al. Primary cutaneous melanoma in hidden sites is associated with thicker tumours-A study of 829 patients. Eur J Cancer 2001, 37:79-82.
12. Schwartz J.L., Wang T.S., Hamilton T.A., et al. Thin primary cutaneous melanomas: associated detection patterns, lesion characteristics, and patient characteristics. Cancer 2002, 95:1562-1568.
13. Karimipour D.J., Schwartz J.L., Wang T.S., et al. Microstaging accuracy after subtotal incisional biopsy of cutaneous melanoma. J Am Acad Dermatol 2005, 52:798-802.
14. Balch C.M., Gershenwald J.E., Soong S.J., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206.
15. Tsao H., Atkins M.B., Sober A.J. Management of cutaneous melanoma. N Engl J Med 2004, 352:998-1012.
16. Statius Muller M.G., van Leeuwen P.A., de Lange-De Klerk D.S., et al. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with stage I or II cutaneous melanoma. Cancer 2001, 91:2401-2408.
17. Morton D.L., Cochran A.J. The case for lymphatic mapping and sentinel lymphadenectomy in the management of primary melanoma. Br J Dermatol 2004, 151:308-319.
18. Johnson T.J., Bradford C.R., Gruber S.B., et al. Staging work-up, sentinel node biopsy, and follow-up tests for melanoma: update of current concepts. Arch Dermatol 2004, 140:107-113.
19. Wang T.S., Johnson T.M., Cascade P.N., et al. Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. J Am Acad Dermatol 2004, 51:399-405.
20. Miranda E.P., Gertner M., Wall J., et al. Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. Arch Surg 2006, 139:831-837.
21. Clark P.B., Soo V., Kraas J., et al. Futility of fluorodeoxyglucose F-18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Arch Surg 2006, 141:284-288.
22. Kirkwood J.M., Ibrahim J.G., Sondak V.K., et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 1996, 14:7-17.
23. Kirkwood J.M., Ibrahim J.G., Sondak V.K., et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial, E1690/S9111/C9190. J Clin Oncol 2000, 18:2444-2458.
24. Cole B.F., Gelber R.d., Kirkwood J.M., et al. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1996, 14:2666-2673.
25. Thomas J.M., Newton-Bishop J., A'Hern R., et al. Excision margins in high-risk malignant melanoma. N Engl J Med 2004, 350:757-766.
26. Veronesi U., Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991, 126:438-441.
27. Balch C.M., Soong S.J., Smith T., et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001, 8:101-108.
28. Cohn-Cedermark G., Rutqvist L.E., Andersson R., et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 2000, 89:1495-1501.
29. Paek S.C. Cutaneous melanoma. Fitzpatrick's Dermatology in General Medicine 2008, 1132-1157. McGraw-Hill Companies, New York. K. Wolff (Ed.).
30. Zitelli J.A., Brown C.D., Hanusa B.H. Surgical margins for excision of primary cutaneous melanoma. J Am Acad Dermatol 1997, 37:422-429.
31. Bub J.L., Berg D., Slee A., et al. Management of lentigo maligna and lentigo maligna melanoma with staged excision: A 5-year follow-up. Arch Dermatol 2004, 140:552-558.
32. Anderson K.W., Baker S.R., Lowe L., et al. Treatment of head and neck melanoma, lentigo maligna subtype: a practical surgical technique. Arch Facial Plast Surg 2001, 3:202-206.